Study quantifies faulty gene's role in ovarian cancer risk

January 19, 2016
Intermediate magnification micrograph of a low malignant potential (LMP) mucinous ovarian tumour. H&E stain. The micrograph shows: Simple mucinous epithelium (right) and mucinous epithelium that pseudo-stratifies (left - diagnostic of a LMP tumour). Epithelium in a frond-like architecture is seen at the top of image. Credit: Nephron /Wikipedia. CC BY-SA 3.0

Women who carry an inherited fault in the BRIP1 gene are three times more likely to develop ovarian cancer than those without it, researchers said Tuesday.

The had already been linked to cancer of the ovaries, but the size of the additional risk has now been quantified in a study in the Journal of the National Cancer Institute.

"Around 18 in every 1,000 develop ovarian cancer, but this risk increases to around 58 women in every 1,000 for women with a fault in the BRIP1 gene," said a statement from Cancer Research UK, whose researchers led the research.

The fault inhibited tissue cells from properly repairing their own DNA, causing genetic damage to build up over time, and leading to cancer, said the team.

The rare but deadly disease, with few early symptoms, is often diagnosed at a very advanced stage, hence its reputation as a silent killer. About 60 percent of patients die within five years.

There is no standard or routine test for early detection of ovarian cancer—a process known as "screening" to boost survival chances by allowing for treatment to begin as soon as possible after disease onset.

The study compared the genes of over 8,000 European women—including a group diagnosed with ovarian cancer, a healthy group, and a third with a family history of the disease.

They found that women who carried the BRIP1 mutation were more likely to be diagnosed with an aggressive form of cancer, at a later stage and at an older age.

"Our work has found a valuable piece of the puzzle behind ovarian cancer and we hope that our work could eventually form the basis of a genetic test to identify women at greatest risk," said Paul Pharaoh, a cancer epidemiology professor at the Cancer Research UK Cambridge Institute.

"Finding these women will help us prevent more cancers and save lives. This would be important in a disease like ovarian cancer, which tends to be diagnosed at a later stage when the chances of survival are worse."

Women with a mutation on the BRCA1 gene, for example, carry a very high risk of developing breast and . Those diagnosed with the variant is found, can opt to surgically remove their breasts and ovaries in order to lower their risk.

Ovarian cancer is the seventh most common cancer in women worldwide, with 239,000 new cases diagnosed in 2012, according to the World Cancer Research Fund International.

Explore further: Screening for ovarian cancer may save lives, new study suggests

Related Stories

Survival improving for women with ovarian cancer

May 12, 2015

(HealthDay)—Women diagnosed with ovarian cancer are now much more likely to survive the disease than they were several decades ago, according to research published online May 6 in Obstetrics & Gynecology.

Different types of ovarian cancer have different causes

November 3, 2015

THE more children a woman has or whether a woman has had her fallopian tubes cut lowers the risk of different types of ovarian cancer to different levels, according to new research presented at the 2015 National Cancer Research ...

Scientists solve breast and ovarian cancer genetic mystery

July 16, 2015

Francis Crick Institute scientists, funded by Cancer Research UK, have solved a decades-old mystery and helped to unravel the genetic cause of some breast and ovarian cancers, according to new research published in the journal ...

Faulty gene connected to ovarian cancer risk

August 9, 2011

In a new study published in Nature Genetics researchers say that women who possess a fault in a gene named RAD51D have a greater risk of developing ovarian cancer than women who do not have this fault and tests are expected ...

Recommended for you

Research finds talc doesn't cause cancer; juries disagree

September 26, 2016

Two lawsuits ended in jury verdicts worth $127 million. Two others were tossed out by a judge who said there wasn't reliable evidence that the talc in Johnson & Johnson's iconic baby powder causes ovarian cancer. So who's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.